We are excited to announce that recruitment of 51 dogs with Atopic Dermatitis for the pivotal proof of concept study has been completed. This is a significant milestone for our company, and we are grateful to everyone who has contributed to this achievement. This study represents a crucial step in our efforts to develop innovative and effective treatments for Atopic Dermatitis, a chronic inflammatory skin condition that affects millions of people worldwide.

Treatment of client owned dogs with natural Atopic Dermatitis is considered one the leading translatable models for human Atopic Dermatitis. We are confident that the results of this study will provide valuable insights into the potential of our product, and we look forward to sharing these findings with the scientific and medical communities during the European Dermatology Development Summit 22-24 May.